Altimmune to Host Virtual R&D Day on March 13, 2025
Altimmune (Nasdaq: ALT) has announced a virtual R&D Day scheduled for March 13, 2025 at 12:00 pm Eastern Time. The event will showcase presentations from Key Opinion Leaders (KOLs) focusing on multiple therapeutic areas for pemvidutide:
- Obesity treatment applications
- MASH (Metabolic Dysfunction-Associated Steatohepatitis)
- Two additional newly FDA-cleared indications
The R&D Day will cover the scientific basis for pemvidutide across these indications, review existing clinical data, and outline development strategies. A significant highlight will be discussing the upcoming topline data from the IMPACT Phase 2b trial in MASH, expected in Q2 2025. The event will be accessible through https://investorday.altimmune.com and the company's website Events section.
Altimmune (Nasdaq: ALT) ha annunciato una giornata virtuale di R&S programmata per il 13 marzo 2025 alle 12:00 ora orientale. L'evento presenterà interventi da parte di Key Opinion Leaders (KOL) focalizzati su diverse aree terapeutiche per il pemvidutide:
- Applicazioni nel trattamento dell'obesità
- MASH (Steatoepatite Metabolica Associata)
- Due ulteriori indicazioni recentemente approvate dalla FDA
La giornata di R&S coprirà le basi scientifiche per il pemvidutide in queste indicazioni, esaminerà i dati clinici esistenti e delineerà le strategie di sviluppo. Un punto saliente sarà la discussione dei prossimi dati preliminari del trial IMPACT di fase 2b in MASH, attesi nel secondo trimestre del 2025. L'evento sarà accessibile tramite https://investorday.altimmune.com e la sezione Eventi del sito web dell'azienda.
Altimmune (Nasdaq: ALT) ha anunciado un Día de I+D virtual programado para el 13 de marzo de 2025 a las 12:00 p.m. hora del Este. El evento contará con presentaciones de Líderes de Opinión Clave (KOL) centradas en múltiples áreas terapéuticas para el pemvidutide:
- Aplicaciones en el tratamiento de la obesidad
- MASH (Esteatohepatitis Asociada a Disfunción Metabólica)
- Dos nuevas indicaciones aprobadas recientemente por la FDA
El Día de I+D cubrirá la base científica del pemvidutide en estas indicaciones, revisará los datos clínicos existentes y esbozará estrategias de desarrollo. Un aspecto destacado será la discusión de los próximos datos preliminares del ensayo IMPACT de fase 2b en MASH, que se esperan en el segundo trimestre de 2025. El evento será accesible a través de https://investorday.altimmune.com y la sección de Eventos en el sitio web de la empresa.
Altimmune (Nasdaq: ALT)는 2025년 3월 13일 오후 12시 동부 표준시로 예정된 가상 연구개발(R&D) 데이를 발표했습니다. 이 이벤트에서는 pemvidutide의 여러 치료 분야에 중점을 둔 주요 의견 리더(KOL)들의 발표가 있을 것입니다:
- 비만 치료 응용
- MASH(대사 기능 장애 관련 지방간염)
- FDA에서 새로 승인된 두 가지 추가 적응증
R&D 데이는 이러한 적응증에 대한 pemvidutide의 과학적 기초를 다루고, 기존 임상 데이터를 검토하며, 개발 전략을 개략적으로 설명할 것입니다. 주요 하이라이트는 MASH에서 진행 중인 IMPACT 2b 단계 시험의 다가오는 주요 데이터에 대한 논의로, 2025년 2분기에 예상됩니다. 이 이벤트는 https://investorday.altimmune.com 및 회사 웹사이트의 이벤트 섹션을 통해 접근할 수 있습니다.
Altimmune (Nasdaq: ALT) a annoncé une journée de R&D virtuelle prévue pour le 13 mars 2025 à 12h00, heure de l'Est. L'événement présentera des interventions de Leaders d'Opinion Clés (KOL) axées sur plusieurs domaines thérapeutiques pour le pemvidutide :
- Applications pour le traitement de l'obésité
- MASH (Stéatohépatite Associée à une Dysfonction Métabolique)
- Deux indications supplémentaires récemment approuvées par la FDA
La journée de R&D couvrira les bases scientifiques du pemvidutide dans ces indications, examinera les données cliniques existantes et esquissera des stratégies de développement. Un point fort sera la discussion des prochaines données préliminaires de l'
Altimmune (Nasdaq: ALT) hat einen virtuellen F&E-Tag angekündigt, der für den 13. März 2025 um 12:00 Uhr Eastern Time geplant ist. Die Veranstaltung wird Präsentationen von Key Opinion Leaders (KOLs) bieten, die sich auf mehrere therapeutische Bereiche für Pemvidutide konzentrieren:
- Anwendungen zur Behandlung von Fettleibigkeit
- MASH (Metabolisch assoziierte Steatohepatitis)
- Zwei weitere neu von der FDA genehmigte Indikationen
Der F&E-Tag wird die wissenschaftlichen Grundlagen für Pemvidutide in diesen Indikationen abdecken, bestehende klinische Daten überprüfen und Entwicklungsstrategien umreißen. Ein bedeutender Höhepunkt wird die Diskussion der bevorstehenden Topline-Daten der IMPACT Phase 2b-Studie in MASH sein, die im 2. Quartal 2025 erwartet werden. Die Veranstaltung wird über https://investorday.altimmune.com und den Bereich Veranstaltungen auf der Website des Unternehmens zugänglich sein.
- None.
- None.
Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDA
GAITHERSBURG, M.D., March 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will host a virtual R&D Day on Thursday, March 13, 2025 beginning at 12:00 pm Eastern Time.
The event will include presentations from renowned Key Opinion Leaders (KOLs) in obesity, MASH and each of the two additional indications, covering the scientific rationale for pemvidutide in each indication, clinical data generated to-date and plans for the continued development of pemvidutide, including the upcoming topline data readout from IMPACT, the Company’s Phase 2b trial in MASH, which is expected in the second quarter of 2025.
The event will be available at https://investorday.altimmune.com and via the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH and other indications. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
danielle.cantey@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Altimmune's (ALT) R&D Day and how can investors access it?
What are the main indications being discussed for pemvidutide at ALT's R&D Day?
When will Altimmune (ALT) release topline data from the IMPACT trial for MASH?
What key topics will be covered during Altimmune's 2025 R&D Day presentation?
